Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
3 clinical-grade skincare creams you really shouldn’t buy online 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Blue Origin New Glenn Explosion Could Delay Launch Operations Until 2028 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Trump Administration Releases New UFO Files and Apollo Mission Records 
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO 
Add as a preferred source on Google
Eli Lilly has announced that the U.S. Food and Drug Administration (FDA) has approved its new therapy, Inluriyo, for the treatment of advanced or metastatic breast cancer in adult patients who have already undergone prior therapy. This milestone approval marks a significant advancement in addressing a challenging form of cancer that often resists standard treatments.
Metastatic breast cancer, also known as Stage IV breast cancer, occurs when cancer spreads beyond the breast and nearby lymph nodes to other organs such as the bones, liver, lungs, or brain. Certain breast cancers develop ESR1 mutations, which cause estrogen receptors to become overly active. While these receptors normally regulate cell growth, their mutation can accelerate cancer progression. Inluriyo directly targets these receptors by binding to and breaking them down, effectively blocking their activity to help slow disease progression.
The FDA’s decision was based on data from a late-stage clinical trial showing that patients treated with Inluriyo had a 38% lower risk of disease progression or death compared to those receiving standard therapies. On average, patients taking Inluriyo went 5.5 months without cancer worsening, versus 3.8 months with other treatments.
Inluriyo is an oral therapy recommended at a daily dose of 400 mg—taken as two 200 mg tablets on an empty stomach. The drug will be available in the U.S. within weeks at a list price of $22,500 per 28-day cycle. Eli Lilly highlighted that the medication carries an embryo-fetal toxicity warning, underscoring the risks of exposure during pregnancy.
The company is also investigating Inluriyo in combination with abemaciclib, another Lilly therapy, for advanced breast cancer, as well as in early-stage disease as adjuvant treatment.
With its approval, Inluriyo offers patients with metastatic breast cancer and ESR1 mutations a new, targeted treatment option that could improve outcomes and provide hope in one of the toughest stages of breast cancer.
